ThroLy score
Thrombosis Lymphoma (ThroLy) predictive score is a multivariable model for thromboembolic events in patients with lymphoma.
Characteristics
ThroLy score was developed and published in 2017 by a group of doctors from Serbia and United States. As a simple model, it was initially internally validated based on individual clinical and laboratory patient characteristics that would classify lymphoma patients at risk for a thromboembolic event. Based on the investigation conducted on derivation and validation cohorts, the variables independently associated with the risk for thromboembolism were: previous venous and/or arterial events, mediastinal involvement, BMI>30 kg/m2, reduced mobility, extranodal localization, development of neutropenia and hemoglobin level < 100g/L.
| Patient characteristics | Assigned score |
|---|---|
| Previous venous thromboembolic event | 2 |
| Reduced mobility | 1 |
| Previous acute miocardial infarction or stroke | 2 |
| Obesity (BMI ≥ 30) | 2 |
| Extranodal localization | 1 |
| Mediastinal involvement | 2 |
| Neutropenia | 1 |
| Hemoglobin˂100g/L | 1 |
Risk classification
Based on the risk score, patients with lymphoma can be classified in three different risk groups.
| Risk group | ThroLy score |
|---|---|
| Low risk | 0-1 |
| Intermediate risk | 2-3 |
| High risk | ≥4 |
Further validations
ThroLy score considers some particular characteristics of lymphoma patients, such as extranodal localization and mediastinal involvement. In addition to having a strong positive predictive value, the score is not limited to either hospitalized or outpatient settings, and does not require non-routine laboratory analyses. In order to be fully applicable in clinical practice, several validation studies have been performed, and several more are ongoing.